Three-dimensional nano-fiber tissue engineering scaffold and preparation method thereof

Abstract

The invention discloses a three-dimensional nano-fiber tissue engineering scaffold. The three-dimensional nano-fiber tissue engineering scaffold comprises a silk fibroin-chitosan-nucleic acid nano-fiber support which is formed by crosslinking silk fibroin-chitosan-nucleic acid nano-fiber filaments prepared from a spinning solution containing chitosan-nucleic acid nano micro-capsules and silk fibroin through a spinning process. The three-dimensional nano-fiber tissue engineering scaffold can provide a good growth micro-environment similar to an extracellular matrix and an enough mechanics support for cells and can be slowly and naturally degraded to release the chitosan-nucleic acid nano micro-capsules carrying nucleic acid, the chitosan-nucleic acid nano micro-capsules can guide carried nucleic acid into the cells, and the local targeting and time-controllable gene therapy effect is exerted. The invention further discloses a preparation method of the three-dimensional nano-fiber tissue engineering scaffold.

Description

technical field [0001] The invention relates to the field of biomedical technology, in particular to a three-dimensional nanofiber tissue engineering scaffold and a preparation method. Background technique [0002] Gene therapy is a biomedical treatment method that uses vectors to deliver target genes into target cells for moderate expression or interference for the purpose of treating diseases. Gene therapy consists of three basic elements: target gene, gene delivery carrier and target cells. Among them, how to obtain efficient, non-toxic, and biodegradable gene delivery vectors has become a technical bottleneck in the field of gene therapy. [0003] The vectors currently used in gene therapy can be divided into two categories: viral gene vectors and non-viral gene vectors. Viral vectors (such as various retroviruses, adenoviruses, poxviruses, herpesviruses, adeno-associated viruses, etc.) have high transfection efficiency in vivo, but there is a small capacity for exogen...

AI Technical Summary

Problems solved by technology

Viral vectors (such as various retroviruses, adenoviruses, poxviruses, herpesviruses, adeno-associated viruses, etc.) have high transfection efficiency in vivo, but there is a small capacity for exogenous genes (about 4.5-30kbp) , poor stability, poor targeting specificity, and potential toxicity and carcinogenicity

Non-viral vectors include liposomes and cationic complexes, which have the advantages of good safety and large gene loading capacity, but have disadvantages such as low transfection efficiency, poor targeting, short effective expression time, and easy removal by blood components.

Images